Authors:
Mohamed E. Salem, John Marshall, Rebecca Feldman, Michael J. Pishvaian, Wafik S. El-Deiry, Jimmy J. Hwang, Emil Lou, Hongkun Wang, Zoran Gatalica, Sandeep K. Reddy, Anthony Frank Shields, Philip Agop Philip
Background
Targeted therapies have a minimal role in PC partly because of the molecular characterization is not well understood. Little is known about the molecular characteristics of subset of PC that doesn’t carry KRAS mutations. Better knowledge would enhance our ability to develop targeted therapies.
Download PublicationCookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |